BioAge Labs is a clinical-stage biopharmaceutical company developing drugs for cardiometabolic diseases — including cardiovascular disease and obesity — by targeting the biology of human aging. BioAge has no approved products and generates no product revenue. The company's discovery platform is built on a proprietary human dataset of longitudinal biobanked samples from aging cohort studies, covering over 25,000 participant profiles and over 150 million molecular data points. By linking protein and metabolite profiles to health outcomes, BioAge identifies biological targets that drive age-related metabolic disease. Its lead program is BGE-102, an oral, once-daily NLRP3 inhibitor targeting chronic systemic inflammation; BioAge is advancing BGE-102 in cardiometabolic disease (reducing cardiovascular risk via hsCRP lowering) and ophthalmology (diabetic macular edema), with Phase 2 trials planned for 2026. Its second program targets the APJ receptor, a pathway activated by the hormone apelin, which BioAge's data linked to longevity and physical function; APJ agonism in preclinical models boosted weight loss and improved body composition on top of GLP-1 receptor agonists, positioning it as a combination add-on for obesity treatment. BioAge funds operations through equity raises and collaborations with Eli Lilly and Novartis. Longer-term, BioAge plans to either self-commercialize or partner its programs with larger pharmaceutical companies in exchange for upfront payments, milestones, and royalties.